One of the biggest conundrums facing those with type 2 diabetes is how aggressively to treat soaring blood sugar levels. Should patients take a mild drug like metformin that might leave their glucose levels a little elevated, increasing their risk of diabetes complications like blindness, amputations due to nerve damage, or kidney disease?
Or should they inject themselves daily with the more potent insulin that could cause side effects like weight gain and hypoglycemia — a condition that causes irritability and light-headedness from low blood sugar.
A new study published earlier this week in JAMA Internal Medicine could help patients and their doctors navigate the difficult decision. It used computer modeling to determine that patients over age 50 with mild to moderate type 2 diabetes — defined as having a hemoglobin A1C level of less than 9 percent — likely get a net negative effect from using insulin; that’s because the small protective benefits they get from lowering their blood sugar from, say, 8.5 percent to 7.5 percent are outweighed by the lower quality of life they experience from insulin’s side effects.
“We were trying to balance two sides of the coin,” said study leader Dr. Sandeep Vijan, a physician–scientist at the Ann Arbor VA Hospital in Michigan. “The benefits of intensive glucose management take a very long time to become apparent so younger patients may benefit from more aggressive therapy than older ones.”
The American Diabetes Association recommends that doctors try to get patients hemoglobin A1C levels — a blood test that’s a more accurate long-term measurement of blood sugar levels — down to about 7 percent using drugs if lifestyle counseling doesn’t work. But many endocrinologists who treat diabetes now believe that’s an over-simplified recommendation.
You have reached the limit of 5 free articles in a month
Stay informed with unlimited access to Boston’s trusted news source.
- High-quality journalism from the region’s largest newsroom
- Convenient access across all of your devices
- Today’s Headlines daily newsletter
- Subscriber-only access to exclusive offers, events, contests, eBooks, and more
- Less than 25¢ a week